Search results
Most RA Patients Meet EMA's JAK Inhibitor Warning Criteria
Medscape· 5 days agoRecent regulatory warnings could mean that four in five patients with RA may not be prescribed JAK...
EXPLAINER: Boosters key to fight omicron, lot still to learn
AOL· 6 days ago“Everything is riskier now because omicron is so much more contagious,” said Dr. S. Wesley Long, who...
Earnings call: Enanta Pharmaceuticals Q2 fiscal results and pipeline updates
Investing.com· 16 hours agoEnanta Pharmaceuticals (NASDAQ: NASDAQ: ENTA ), a biopharmaceutical company focused on developing...
Earnings call: Cardiff Oncology reports on CRDF-004 trial progress
Investing.com· 5 days agoCardiff Oncology, a biopharmaceutical company focused on developing new treatments for cancer, has...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via Yahoo Finance· 5 days agoIt’s important to note that the vaccine maker, which employs about 5,100 people as of June 2023 and...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune· 5 days agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the market, its COVID-19 vaccine called Spikevax. The company’s first quarter revenue is down ...
Biotech’s bind over China bill
Politico· 4 days agoBancel suggested the shot’s presentation — a pre-filled syringe — could be a game-changing differentiator for busy health care providers. GSK and Pfizer make RSV vaccines ...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
AOL· 5 days agoThe dark days of the pandemic are finally in the past for most of us—and that seems to be reflected in the earnings for Moderna, whose revenue is dependent on sales of its COVID-19 vaccine.